Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chang Gung Memorial Hospital, Taoyuan
Dendritic cell vaccine safe in advanced hepatocellular carcinoma patients
October 26th, 2005
A tumor lysate-pulsed dendritic cell vaccine was safe in advanced hepatocellular carcinoma patients. "Hepatocellular carcinoma (HCC) is a common and rapidly progressing malignancy. Current treatment options for advanced HCC are limited. This clinical study of dendritic cell (DC)-based immunotherapy for HCC enrolled 31 patients with advanced HCC. DCs, propagated from peripheral blood monocytes, were pulsed with autologous tumor lysates to treat HCC. The first 14 patients underwent pulsed therapy with five courses of DC vaccination intravenously at weekly intervals. The other 17 patients underwent monthly boost vaccinations after the initial pulsed therapy," scientists in...
Source: Elder Law Weekly (2005-10-26)
|
